CHARGE syndrome

CHD7 - CHARGE syndrome

This test is available for the following conditions:

• Conditions > Intellectual Disability > CHARGE syndrome
• Conditions > Multiple congenital anomalies (MCA) > CHARGE syndrome
• Conditions > Hearing impairment > CHARGE syndrome
• Conditions > Endocrine > CHARGE syndrome
• Conditions > Vision impairment / blindness > CHARGE syndrome

This product is also part of the following panels:

• WES congenital heartdisease ¹ (100.0% *)
• WES craniofacial anomalies (100.0% *)
• WES Disorders/differences of sex development (DSD) / Primary adrenal insufficiency (100.0% *)
• WES hearing impairment (including GJB2) (100.0% *)
• WES heart disorders¹ (100.0% *)
• WES hypogonadotropic hypogonadism (Kallmann) (100.0% *)
• WES intellectual disability (100.0% *)
• WES Mendelian inherited disorders (100.0% *)
• WES Mendelian inherited disorders (100.0% *)
• WES orofacial clefting (100.0% *)
• WES primary immunodeficiencies (100.0% *)
• WES vision disorders (100.0% *)

* % of the coding region of this gene has a coverage of >20x. (Without % information : This is a non-coding gene for which coverage statistics could not be determined)

Turnaround time
Complete analysis: 8 weeks / Targeted analysis: 4 weeks

Method

• Sequence analysis of all coding exons and flanking intron-exon boundaries

Remarks
MLPA analysis only upon request.

OMIM: 608892
Performing laboratory: Radboudumc
Authorized material(s): EDTA blood, Isolated DNA, Buccal mucous membrane

---

CHD7 - CHARGE syndrome (MLPA)

This test is available for the following conditions:

• Conditions > Intellectual Disability > CHARGE syndrome
• Conditions > Multiple congenital anomalies (MCA) > CHARGE syndrome
• Conditions > Hearing impairment > CHARGE syndrome
• Conditions > Vision impairment / blindness > CHARGE syndrome

This product is also part of the following panels:

• WES congenital heartdisease ¹ (100.0% *)
• WES craniofacial anomalies (100.0% *)
• WES Disorders/differences of sex development (DSD) / Primary adrenal insufficiency (100.0% *)
• WES hearing impairment (including GJB2) (100.0% *)
• WES heart disorders¹ (100.0% *)
• WES hypogonadotropic hypogonadism (Kallmann) (100.0% *)
• WES intellectual disability (100.0% *)
• WES Mendelian inherited disorders (100.0% *)
• WES Mendelian inherited disorders (100.0% *)
• WES orofacial clefting (100.0% *)
• WES primary immunodeficiencies (100.0% *)
• WES vision disorders (100.0% *)

* % of the coding region of this gene has a coverage of >20x. (Without % information : This is a non-coding gene for which coverage statistics could not be determined)

Turnaround time
Complete analysis: 8 weeks / Targeted analysis: 4 weeks

Method

• Deletion/duplication analysis (MLPA)

OMIM: 608892
Performing laboratory: Radboudumc
Authorized material(s): EDTA blood, Isolated DNA, Buccal mucous membrane

---